



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Preventing influenza and influenza like illness during Covid-19 pandemic: A call for action

Dear Editor,

We read with interest the article by Grech et al. [1] on the influenza vaccination in the COVID-19 era. The current COVID-19 pandemic poses the need to take preventive evidence-based actions by policy makers with the aim of both curbing the spread of the infection and protecting people susceptible to a severe disease. In our recent article [2] we highlighted that patients with history of recent influenza or influenza like illnesses (ILI) has been found to incur greater risk and severity of COVID-19; we hypothesized that previous ILI or influenza could therefore represent a predisposing factor for subsequent COVID-19 infection. Findings of our study showed that 63.6% of 190 COVID-19 patients reported in their clinical history a recent ILI (1–3 weeks prior to the appearance of COVID-19 related symptoms); previous flu vaccination was reported in only 26.3% of patients. To date, concerns is arising in the northern hemisphere in view of the coming soon of fall and winter seasons which are notoriously overburdened by high rates of influenza and ILIs [3]. Given these findings, we suggest policy-makers actions aimed at:

1) Providing vaccinations against influenza and pneumonia:

Vaccination against influenza should be provided both to minimize the individual susceptibility to Covid-19 [3] and to avoid superimposed infection from influenza viruses in patients suffering from Covid-19 [4]; moreover, as influenza and ILIs can disguise the diagnosis of COVID-19 (since they may have a similar symptomatology) flu vaccination may help disclosure COVID-19 in people suffering from SARS-CoV-2 infection. The CDC recommends that all people 6 months and older get a yearly flu vaccine, in line with existing literature that shows the effectiveness of flu vaccination to prevent influenza [5]. Pneumococcal and *Haemophilus influenzae* type B vaccinations should be also provided to avoid superimposed pneumonia in patients affected by Covid-19.

2) Maintaining social distancing and strengthening hygiene measures to prevent the spread of influenza and ILIs.

Given the airborne transmissibility of pathogens causing Influenza and ILIs [6], actions should be taken in order to prevent the spread of such infections by adoption of social distancing in both working and community settings. Hygiene measures (i.e. face masks and hand hygiene) should be adopted and strengthened, since they have been already proved effective to prevent influenza and ILIs; in particular: avoiding close contact with sick people, limiting contact with others while sick (by staying home for at least 24 h after flu-like symptoms appear if needed), covering one's nose and mouth with a tissue while coughing or sneezing and throwing the tissue in the trash after use, keeping hands clean by regular washing with soap and water, avoiding

touching mouth, nose, and eyes, and cleaning and disinfecting surfaces [7].

3) Protecting people recently affected by influenza or ILIs and, therefore, susceptible to COVID-19.

In our study [2] we speculated previous influenza and ILI being a potential trojan horse for COVID-19; given this hypothesis, we suggest that, in addition to the well-known conditions of individual susceptibility for severe COVID-19 (i.e. advanced age, cardiac injury, COPD, immunodepression, cancer, etc.), recent influenza or ILI are other host risk factors to be considered. Therefore, we think that people recently affected by influenza or ILI should be considered as "fragile" for COVID-19 and strength protected from the infection.

Declaration of competing interest

We declare no competing interests.

References

- [1] V. Grech, M. Borg, Influenza vaccination in the COVID-19 era, *Early Hum. Dev.* 148 (2020), 105116, <https://doi.org/10.1016/j.earlhumdev.2020.105116>.
- [2] G. Ceccarelli, G. d'Ettore, C.M. Mastroianni, G. d'Ettore, Is previous influenza-like illness a potential trojan horse for COVID-19? *Crit. Care* (2020) <https://doi.org/10.1186/s13054-020-03226-5>.
- [3] J.D. Silverman, N. Hupert, A.D. Washburne, Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States [published online ahead of print, 2020 Jun 22], *Sci. Transl. Med.* (2020), <https://doi.org/10.1126/scitranslmed.abc1126> eabc1126.
- [4] M. Madjid, P. Safavi-Naeini, S.D. Solomon, O. Vardeny, Potential effects of coronaviruses on the cardiovascular system: a review, published online ahead of print, 2020 Mar 27, *JAMA Cardiol.* (2020), <https://doi.org/10.1001/jamacardio.2020.1286>.
- [5] Centers for Diseases Control and Prevention (CDC), Vaccines and preventable diseases, available at, www.cdc.gov/vaccines/vpd/, 2016. (Accessed 8 May 2020).
- [6] R. Zhang, Y. Li, A.L. Zhang, Y. Wang, M.J. Molina, Identifying airborne transmission as the dominant route for the spread of COVID-19, *Proc. Natl. Acad. Sci. U. S. A.* 117 (26) (2020) 14857–14863, <https://doi.org/10.1073/pnas.2009637117>.
- [7] The Lancet, Preparing for seasonal influenza, *Lancet* 391 (10117) (2018) 180, [https://doi.org/10.1016/S0140-6736\(18\)30087](https://doi.org/10.1016/S0140-6736(18)30087).

Gabriele d'Ettore^a, Giancarlo Ceccarelli^{b,c,*}, Claudia Pinacchio^c, Massimo Ciccozzi^d, Gabriella d'Ettore^{b,c}

^a Unit of Occupational Prevention and Protection, ASL Lecce, Lecce, Italy

^b Azienda Ospedaliero-Universitaria Policlinico Umberto I, Rome, Italy

^c Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

^d Department of Medical Statistics and Epidemiology Unit, Campus Bio-Medico University, Rome, Italy

<https://doi.org/10.1016/j.earlhumdev.2020.105156>

Received 5 August 2020; Accepted 11 August 2020

Available online 12 August 2020

0378-3782/© 2020 Elsevier B.V. All rights reserved.

* Corresponding author at: Department of Public Health and Infectious Diseases, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Italy.

E-mail address: giancarlo.ceccarelli@uniroma1.it (G. Ceccarelli).